Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,201
datasets available to search
ShareScore release 0.9.0
Dataset results
1,201 results for “oncology”
Dataset related to article "Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term oncological outcomes "
<p>This record contains raw data related to article “Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term oncological outcomes"</p> <p>Abstract</p> <p><strong>Purpose: </strong> To define predictors of malignancy after Testis sparing surgery (TSS) in patients referring to a fertility center with incidental small testicular lesions. Sub analyses were performed to assess predictors of Leydig cell hyperplasia and Leydig cell tumor.</p> <p><strong>Materials and methods: </strong> We performed a retrospective analysis of a single institutional database including patients treated with TSS between 2002 and 2020. All patients who underwent TSS as a first line surgical approach for incidentally detected lesions found during fertility evaluation were included.</p> <p><strong>Results: </strong> Data of 64 patients were collected. The median follow up was 58 months and no recurrences were observed. At univariable logistic regression multifocal lesions, hypervascularization, microlithiasis, age and lesion size were significantly associated with malignancy. At multivariable logistic regression lesion dimension, hypervascularization and multifocal lesions were predictors of malignancy. Lesions smaller than 5 mm proved to be benign in 96.6% of the cases (32/33). Intraoperative color of the lesion and US pattern of vascularization were predictors at multivariable logistic regression for Leydig cell hyperplasia and Leydig cell tumor.</p> <p><strong>Conclusion: </strong> Ultrasonographic characteristics and intraoperative appearance of the lesion can predict the malignant nature of small testicular lesions, guiding their surgical management in patients referring to a fertility center. Based on our experience, clinicians may safely perform TSS in carefully selected patients.</p> <p> </p>
Dataset related to article: "Different Oncologic Outcomes in Early-Onset and Late-Onset Sporadic Colorectal Cancer: A Regression Analysis on 2073 Patients"
<p>This record contains data related to article: "Different Oncologic Outcomes in Early-Onset and Late-Onset Sporadic Colorectal Cancer: A Regression Analysis on 2073 Patients"</p> <p>The incidence of colorectal cancer (CRC) is increasing in the population aged ≤ 49 (early-onset CRC-EOCRC). Recent studies highlighted the biological and clinical differences between EOCRC and late-onset CRC (LOCRC-age ≥ 50), while comparative results about long-term survival are still debated. This study aimed to investigate whether age of onset may impact on oncologic outcomes in a surgical population of sporadic CRC patients. Patients operated on for sporadic CRC from January 2010 to January 2022 were allocated to the EOCRC and LOCRC groups. The primary endpoint was the recurrence/progression-free survival (R/PFS). A total of 423 EOCRC and 1650 LOCRC was included. EOCRC had a worse R/PFS (<em>p</em> &lt; 0.0001) and cancer specific survival (<em>p</em> &lt; 0.0001) compared with LOCRC. At Cox regression analysis, age of onset, tumoral stage, signet ring cells, extramural/lymphovascular/perineural veins invasion, and neoadjuvant therapy were independent risk factors for R/P. The analysis by tumoral stage showed an increased incidence of recurrence in stage I EOCRC (<em>p</em> = 0.014), and early age of onset was an independent predictor for recurrence (<em>p</em> = 0.035). Early age of onset was an independent predictor for worse prognosis, this effect was stronger in stage I patients suggesting a potentially-and still unknown-more aggressive tumoral phenotype in EOCRC.</p>
Dataset related to article "Why are they not coming back? A single-center follow-up study on oncological women oocyte's storing for fertility preservation"
<p>This record contains data related to article “Why are they not coming back? A single-center follow-up study on oncological women oocyte's storing for fertility preservation"</p> <p> </p> <p>Abstract</p> <p><strong>Introduction: </strong>Oocyte cryopreservation is a valid option for female cancer patients to preserve fertility. The number of patients undergoing fertility preservation (FP) cycles has increased over the past years. Nevertheless, the rates of patients returning to use their cryopreserved material have shown to be considerably low, ranging from 5-8%, but significant data regarding the reasons of such low return rates are scarce.</p> <p><strong>Methods: </strong>This study is a single-center follow-up retrospective study evaluating the return rate of oncological women who underwent FP at a tertiary care Fertility Center and assessing the reasons influencing the patients who did not return. Data about patients who returned to attempt pregnancy were retrieved from internal registries. Non-returned patients were assessed with a standardized phone survey investigating health condition, marital status and family projects, spontaneous conceptions, and the reasons why they had not returned to use their gametes. A univariate analysis between returned and non-returned patients was performed.</p> <p><strong>Results: </strong>Of the 397 patients who received counseling about FP, 171 (43.1%) underwent oocyte cryopreservation between 2001 and 2017. Nine (5%) died, and 17 (10%) were lost at follow-up. A total of 20 patients (11.7%) returned and 125 did not. In the non-returned group, 37 (29.6%) did not have a partner, 10 (8%) had a previous spontaneous conception, and 15 (12%) had recurrent malignancy at the time of follow-up. In the univariate analysis, younger age at freezing (31.8±6.2 vs. 35.2±4.7; p 0.018), lack of a partner (p 0.002), type of cancer (other than breast cancer; p 0.024) were the significant factors in the non-returned group. As for the personal reason for not coming back, patients mainly answered as follows: lack of a partner (29, 23.2%), the desire for spontaneous motherhood (24, 19.2%), previous spontaneous pregnancies after FP procedures (16, 12.8%), and still ongoing hormonal therapy for breast cancer (13, 10.4%). All patients confirmed their will to keep the storage of their oocytes.</p> <p><strong>Discussion: </strong>The impact of a cancer diagnosis on a woman's maternal desire, sentimental status and life priorities should be studied more thoroughly. Studies investigating hormonal therapy suppression in breast cancer patients seeking pregnancy should be encouraged.</p> <p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov, identifier <a href="http://clinicaltrials.gov/show/NCT05223764">NCT05223764</a>.</p> <p> </p>
Factors contributing to Chimeric Antigen Receptor T-cell Therapy efficacy in pediatric oncology patients
GEO Series GSE187438. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Expression Project for Oncology (expO)
GEO Series GSE2109. Homo sapiens. 2158 samples. Type: Expression profiling by array.
Programmed Death Ligand 1 in Tumor Margins with Implications of Regulation by Interferon Gamma, and a Novel Immuno-Oncologic Transcriptional Signature for Malignant Transformation
GEO Series GSE219053. Homo sapiens. 10 samples. Type: Expression profiling by array.
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm.
Enabling Whole Genome Sequencing Analysis from FFPE Specimens in Clinical Oncology
This study includes whole genome sequencing from 44 pediatric patients at Memorial Sloan Kettering derived from formalin-fixed paraffin-embedded (FFPE) tissue. This dataset was used to train and validate a classification strategy called FFPErase for detecting artifact mutations from FFPE damage.
AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)
GEO Series GSE229503. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis"
<p>This record contains raw data related to article "Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Breast cancer (BC) is very uncommon in young women (YW) and it is unclear whether a BRCA mutation has prognostic implications. Our aim was to evaluate the characteristics of YW with BC by comparing the long-term oncological results between BRCA-mutation carriers and non-carriers.</p><p><strong>Methods: </strong>We retrospectively reviewed all the consecutive YW (aged 18-40 years) diagnosed with BC. Endpoints were disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS).</p><p><strong>Results: </strong>63 YW with a BRCA mutation were compared with 339 YW without BRCA mutation. BRCA-mutation carriers were younger (60.3% versus 34.8% if age ≤ 35 years, <i>p</i> = 0.001) and presented with more aggressive tumors (66.7% versus 40.7% if G3, <i>p</i> = 0.001; 57.2% versus 12.4% if biological subtype triple-negative, <i>p</i> = 0.001; 73.0% versus 39.2% if Ki67 ≥ 25%, <i>p</i> = 0.001). Non-carriers presented significantly better DFS, DDFS, and OS compared with BRCA-mutation carriers. Neoadjuvant chemotherapy was found to be an independent protective factor for OS in BRCA-mutation carriers.</p><p><strong>Conclusions: </strong>BC is more likely to present at a younger age (≤ 35 years) and with more aggressive characteristics (G3, triple-negative, Ki67 ≥ 25%) in YW with BRCA mutation compared with their non-mutated counterparts. Young BRCA-mutation carriers showed a poorer prognosis in terms of recurrence and survival compared with non-carriers. The implementation of neoadjuvant chemotherapy may improve survival in YW with BC and BRCA mutation.</p>
Dataset related to article "Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center "
<p>This record contains raw data related to article “Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center"</p> <p><strong>Introduction: </strong> Salvage mastectomy is considered the treatment of choice for ipsilateral breast cancer recurrence (IBCR), even if a second breast-conserving surgery (BCS) is feasible. The purpose of this study was to describe the characteristics of IBCR patients, to compare the 2 therapeutic options in terms of long-term outcomes, and to identify independent factors that may predict the type of treatment.</p> <p><strong>Patients and methods: </strong> A total of 309 IBCR patients who underwent either repeat BCS or mastectomy were identified. All the analyzed patients with IBCR had true recurrence.</p> <p><strong>Results: </strong> Repeat BCS and salvage mastectomy were performed in 143 and 166 patients, respectively. Age < 65 years (59.6% vs 37.1% if age ≥ 65 years; odds ratio, 2.374; 95% confidence interval, 0.92-5.24; P = .018) and disease-free interval < 24 months (15.7% vs 10.5% if disease-free interval ≥ 24 months; odds ratio, 2.705; 95% confidence interval, 1.42-5.97; P = .007) were found to significantly increase the probability of receipt of mastectomy. Disease-free survival rates at 3, 5, and 10 years were 79.2%, 68.2%, and 36.9%; and 77.2%, 65.9%, and 55.3% in patients receiving repeat BCS or mastectomy, respectively (P = .842). Overall survival rates at 3, 5, and 10 years were 95.4%, 91.4%, and 68.5%; and 87.3%, 69.3%, and 57.9%, respectively, in patients receiving repeat BCS or mastectomy (P = .018).</p> <p><strong>Conclusion: </strong> Salvage mastectomy should not be considered the only treatment option for IBCR. A second BCS can still be evaluated and proposed to IBCR patients, with acceptable locoregional control and survival. The risk of poor long-term prognosis after mastectomy should be shared with the patient.</p>
New approach to implement cancer patients care: The ValPeROC experience from an Italian oncology network
<p>Objective: Primary goal of the Oncology Campania Network (ROC) was to reduce cancer delay and care fragmentation through the establishment of cancer-specific Multidisciplinary Oncologic Groups (GOM) and therapeutic and diagnostic assistance paths (PDTA). Methods: five Cancer Centers of the ROC, with their own cancer specific GOM were selected. In our analysis we have focused on four neoplasms: lung, colon, ovarian and prostate cancers. The median time for pre-GOM and GOM Times were calculated for each tumor site. Univariate and Multivariate logistic regressions were performed to individuate risk factors for pre-GOM and GOM Time. Results: Significant differences were observed for prostate cancer compared to other patients either for pre-GOM or GOM Times. Significant risks were found for ovarian and prostate cancer in pre-GOM time and for prostate cancer in GOM-Time. Conclusions: This experience will produce knowledge and data to guide decision-making and to manage more effectively the challenges of fighting cancer in Campania region. The ValPeROC study evaluates, for the first time, the ROC activity, through the analysis of key performance indices. Pre-GOM and GOM Time represent the quality of the entire regional health system and are useful to define models which can evaluate the performance of the ROC over time.</p>
Data related to article "Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)"
<p>xls clinical dataset on glioma Istituto Besta patients involved in the study mentioned at title.</p>
Laser Therapy in Heavily Treated Oncological Patients Improves Vaginal Health Parameters
Open the record for dataset details and reuse information.
Italian Association of Pediatric Hematology, Oncology, and Science
A fundamental task of the Association is to promote and encourage all initiatives aimed at increasing and enhancing the humanization of care for children with haematological-oncological conditions and their families.
Children's Oncology Group
The Children's Oncology Group (COG), a National Cancer Institute supported clinical trials group, is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer. All COG members must maintain the highest standards for treating patients with cancer and follow COG-defined protocols to prove their scientific, medical and ethical scientific expertise.
Pediatric Oncology Group of Ontario Networked Information System 2020
Childhood Cancer in Ontario: The 2020 POGO Surveillance Report is the third in a series of POGO childhood cancer surveillance statistical reports. It provides recent childhood cancer statistics in Ontario related to incidence (new cancers), mortality (deaths), survival (percentage of children who survive at least 5 years after diagnosis) and estimates of prevalence (number of people alive with a past diagnosis of cancer during childhood) by sex, age group and cancer type for children aged 0-14 years and diagnosed with cancer in Ontario. Information on trends and changes in these measures over time are also presented. This work enhances data-driven quality improvement by ensuring that the right data are available and being used to inform an effective childhood cancer system.
Implementation of pediatric precision oncology into clinical practice: The individualized Therapies for Children with cancer program "iTHER"
<p>Published in: European Journal of Cancer</p> <p>https://doi.org/10.1016/j.ejca.2022.09.001</p>
Gynecologic Oncology Group Foundation
The GOG Foundation is a nonprofit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva. Our institutions and investigators are essential contributors to advancements in treatment regimens, surgical procedures, quality of life analyses, and prevention knowledge. The results of GOG Foundation clinical trials have influenced the standard of care for numerous malignant gynecologic neoplasms.
NRG Oncology Biospecimen Bank
The NRG Oncology Biospecimen Bank (NRG BB) is the biorepository for biospecimens collected from patients enrolled in NRG clinical trials (as well as the legacy Group trials of NSABP, RTOG, and GOG). This collection includes but is not limited to paraffin-embedded and frozen tissues; blood products such as whole blood, plasma, serum, and buffy coats; nucleic acids (DNA, RNA); urine and stool. Extensive clinical and outcome data exist for most of these biospecimens and can be provided by the NRG Statistical and Data Management Center (SDMC). The NRG BB provides annotated, de-identified, and, if required, anonymized biospecimens to qualified investigators who comply with National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Biobanks access policies and who have funding to support their project.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.